VisMederi and the International Vaccine Institute have formed a new partnership to accelerate vaccine development in developing countries.
VisMederi, a company at the forefront of research and innovation in the life sciences and biotechnology sectors, is pleased to announce the signing of a Memorandum of Understanding (MOU) with the International Vaccine Institute (IVI), a prestigious international nonprofit institution engaged in vaccine research and development for developing countries.
Executives from both institutions signed the agreement in Siena.
Present for IVI were general director Jerome Kim, Laura Plant, Head of External Affairs at the European Regional Office, and Annette Kraus, Senior Research Scientist.
The main purpose of this agreement is to enhance collaboration in the areas of vaccine research and development, training, and capacity building for the benefit of global public health. Areas of cooperation will include the joint development of programs aimed at improving health systems and infrastructure in developing countries, but most importantly, sharing expertise and resources to accelerate the introduction of new vaccines.
“With this partnership, we will be able to support companies involved in vaccine production for developing countries in an even more structured way.” Explained by Emanuele Montomoli
chief scientific officer and founder of VisMederi. “Together, we can more efficiently address global health challenges that threaten the most vulnerable populations. VisMederi will provide expertise in the segment of clinical trials and evaluation of the efficacy of vaccines for emerging pathogens. These studies are strategic to be able to make new, effective vaccines available quickly, especially in the poorest areas.”
The partnership also includes joint initiatives to participate in various research calls, such as the European and Developing Countries Clinical Trials Partnership (EDCTP), and new opportunities in the area of infectious disease prevention from various European and international agency programs.
“This partnership represents an important step toward our common goal of scientific innovation to benefit global health,” said Sara Pugliese, chief executive officer of VisMederi Holding. “By joining forces, we can increase our technical and strategic impact and bring effective solutions to the most needy settings.”
The IVI delegation had the opportunity to visit the new “operational” facility in Colle di Val d’Elsa on the same day, where new research and development laboratories are in the process of starting up and will officially inaugurate in June. The visit ended with an informal meeting among members of the delegation.
